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Acquired Irrunune Deficiency Syndrome (AIDS) has been 
the focus of vaccinologists since the virus that causes the 
disease was first described in 1984. Wi th all of AIDS 
unique characteristics, the virus to date has evaded the 
successful development of a preventative vaccine. This 
thesis addresses the problems associated with an AIDS 
vaccine being developed, current research that has been 
sought as a cure to the disease, and what steps the 
potential vaccines have to undergo before they are 
available for human usage. 
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Is Prevention Possible? 
The Search for a Vaccine for the HIV Virus 
Since the HIV epidemic began in the 1980s, it is 
estimated that more than 28 million people have been 
infected with HIV. Of that 28 million, there are 
approximately 22 million people currently living with HIV 
and 3 million new infections being added to the total each 
year worldwide. Ninety percent of the 28 million global 
infections have occurred in developing countries, with 65 
percent in countries of sub-Saharan Africa and another 20 
percent in countries of South and Southeast Asia (Heyward 
et aI, 1998). Over the past decade and a half, the HIV 
epidemic has progressed virtually unimpeded to affect 
nearly every country on every continent in the world 
(Heyward et aI, 1998). 
Since 1984 when the Human Immunodeficiency Virus (HIV) 
was singled out as the causative agent in Acquired Immune 
Deficiency Syndrome, preventative measures have been sought 
by medical researchers in hope that in ten to fifteen years 
from now, a vaccine will be discovered that can eliminate 
this deadly disease from the earth. AIDS is caused by a 
DNA retrovirus and can be passed on from infected to 
uninfected individuals through four main modes of 
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transport: blood, semen, vaginal fluid, and breast milk. 
Its mode of operation is to target and infect the CD 4+ 
cells of the immune system which are vital to the immune 
responses that our body use to eliminate diseases caused by 
microbial agents. 
Entering U.S. society in the early 1980s first in the 
gay and intravenous drug using populations, AIDS has . put 
fear into countless numbers of people because there 
presently is not a cure for the disease, and once it 
develops following HIV infection the chances of long term 
survival are minimal. Although we actually know how to 
prevent HIV infection through effective prevention programs 
of education, HIV testing and counseling, condom promotion, 
serological screening of donated blood, needle exchange, 
and other interventions, the HIV epidemic continues, and, 
in some areas of the world such as Southeast Asia, Eastern 
Europe, and Russia, it is expanding exponentially (Heyward 
et al, 1998). Since the virus infects the immune system, 
the use of drug therapy can only help to lengthen the 
amount of time it takes the disease to overwhelm and 
debilitate the immune system (Des Jarlais et al 1997). 
There is no question that a safe, effective HIV preventive 
vaccine is urgently needed to bring the HIV IAIDS epidemic 
under control, and it is our hope and belief that modern 
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medical technology will be able to overcome this disease, 
as it has for so many countless others. 
Vaccinol.ogy 
Scientists in the past have been able to find 
preventative vaccines for the use of the general population 
since cowpox was first used to vaccinate for the human 
disease of small pox. From numerous achievements, a 
science devoted solely to the development of vaccines has 
been founded. Vaccinology, the engineering and development 
of vaccines to prevent infectious diseases, has been 
challenged for a vaccine which protects against AIDS 
because it is so unique in its mode of infection, being a 
primarily sexually transmitted disease, and the role it 
takes in the immune system once it has infected an 
individual (Hilleman, 1998). 
Though misguided in its first decade, current vaccine 
research is directed to use any and all viral antigens and 
to elicit both cell-mediated and antibody immune responses, 
with memory at the mucosal sites of the body, which is the 
primary portal of entry (Hilleman, 1998). 
Prohl.ems Associated with the Devel.opment of an Effective 
HIV Vaccine 
Al though dozens of potential vaccines have been under 
development ever since HIV was discovered in 1984, most 
3 
--
have reached a dead end in the laboratory and none has yet 
reached the phase III stage where it can be widely tested 
to see if it is effective (Perlman, 1998). 
The development of a safe and effective vaccine for 
the prevention of AIDS has thus far proven to be extremely 
difficult, at least in part due to complexities associated 
with HIV-1 and its pathogenesis (Graham and Wright, 1995). 
Unlike some other viruses, HIV can be transmitted and can 
exist in the body not only as free virus but also within 
infected cells, sometimes for long periods of time in a 
latent provirus. Another. factor complicates any attempt to 
provide protection from HIV infection. According to the 
World Health Organization (WHO), 80 percent of all HIV 
transmission worldwide occurs sexually. Thus, to be 
effective, an HIV vaccine may need to stimulate mucosal 
immunity. Mucosal immune cells that line the respiratory, 
digestive and reproductive tracts and those found in nearby 
lymph nodes are the first line of defense against 
infectious organisms. Unfortunately, relatively little is 
known about how the mucosal immune system protects against 
viral infection (Johnston, 1997). 
Perhaps the most difficult challenge for vaccine 
researchers is that the major target of HIV is the immune 
system itself. HIV infects the key CD4+ T cells that 
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regulate the immune response, modifying or destroying their 
ability to function (Johnston, 1997). After infection into 
the host cell, the RNA of HIV is reverse transcribed into 
DNA and incorporates its genetic material in the host cell 
chromosome (Behforouz, 1999) . If the cell reproduces 
itself, each new cell also contains the HIV genes. There 
the virus can hide its genetic material for prolonged 
periods of time until the cell is activated and makes new 
viruses. During a clinical dormancy period, the disease 
can still be transferred to other individuals although the 
carrier may appear to be clinically asymptomatic. 
Understanding how HIV disease evolves, especially 
during early infection is 
researchers (Johnston, 1997). 
a high priority of AIDS 
Scientists have shown that 
no true period of biological latency exists in HIV 
infection. After entering the body, the virus rapidly 
disseminates, homing to the lymph nodes and related organs 
where it replicates and accumulates in large quantities 
(Johnston, 1997). The filtering system in these lymphoid 
organs, which are so effective at trapping pathogens and 
initiating an immune response, may help destroy the immune 
system because HIV infects the steady stream of CD4+ T 
cells that travel to the lymph organs in response to HIV 
infection (Johnston, 1997). 
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correlated with in vitro growth characteristics of the 
virus, some of which may be relevant for vaccine 
development. Some strains referred to as 'slow/low' , 
replicate slowly and to low titer in T-cell lines, and to 
induce syncytia (S1) {54-56}. Most viruses isolated from 
recently infected persons exhibit the slow/low phenotype, 
whereas viruses isolated from patients with more advanced 
disease are of the rapid/high phenotype. These findings 
suggest that HIV is usually trans fer red with a phenotype 
that doesn't replicate rapidly, but later evolves to the 
rapid/high phenotype once it has been in the body. 
The recent description of individuals transiently 
infected with H1V-1, as well as persons who survived HIV-1 
infection for more than 15 years, indicates the ability of 
the immune response of certain individuals to control HIV-1 
infection (Hulskotte et aI, 1998). Moreover, vaccination-
challenge experiments in macaques infected with simian 
immunodeficiency virus (S1V) have shown that protection 
against infection or development of disease may be achieved 
in the absence of sterilizing immunity, suggesting that the 
goals for AIDS vaccine development may have to be refined 
(Hulskotte et aI, 1998). This may suggest that the 
ultimate goal of HIV research may have to be directed to 
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__ the prevention of disease rather than immunity through 
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infection (Behforouz, 1999). However, development of true 
immunity to this virus in humans has not been clearly 
demonstrated and immune correlates of protective immunity 
remain uncertain (Hulskotte et al, 1998). 
One of the most unique properties of the AIDS virus 
that makes it so elusive to the vaccinologists is its 
ability to mutate while maintaining the unique properties 
that are so destructive to the human immune system (Mortara 
et al, 1998). With multiple genetic subtype of HIV-1 
differing up to 30% of nucleotides in their envelope coding 
sequences, having been identified in the global epidemic, 
it is easy to see why thus far it has been so difficult to 
find a vaccine that is able to give immunity to such a 
large diversified group of envelope proteins (Mortara et 
al, 1998). In the United States alone, where HIV-1 
infection with subtype B predominates, the interisolate 
diversity in the viral envelope is 15% or more (McCutchan 
et al, 1998) . Although it is recognized that geographic, 
temporal, and demographic variables can affect the genetic 
diversity of HIV-1 strains, there have been few 
opportunities to evaluate these factors by population-based 
sampling, adding to the problems associated with the 
diversity seen in the virus. 
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-Another maj or problem in developing any AIDS vaccine 
is finding a system that exploits two distinct aspects of 
the human immune system, said Dr. Jay Levy, the virologist 
a t the Uni versi ty of California at San Francisco who was 
one of the discoverers of HIV (Perlman, 1998). One function 
of the immune system that a vaccine must trigger is to 
induce the body to release antibodies, specialized proteins 
that attack the virus as soon as it invades, Levy said. The 
other is to mobilize cells that can either kill the virus 
directly or prevent it from replicating after it has begun 
infecting -- even when the virus is latent and lying hidden 
within the tissues it has infected (Perlman, 1998). 
Another problem in the development of an AIDS vaccine 
is that the disease is only in the human population, and 
while other animals may get immune deficiency syndromes, 
there is not a really good model of disease for HIV in 
animals (Behforouz, 1999). Chimps get infected when they 
are inoculated, but apparently they do not get sick 
(Behforouz, 1999). 
Researchers trying to develop a vaccine also run into 
problems involving the long incubation period 
characteristic of HIV, so it takes a very long time, 
sometimes years to be able to see how effective the vaccine 
would be (Behforouz, 1999). 
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Cognizant of all of these problems, along with others 
not yet delineated, scientists have delved further into the 
study of the virus, so that one of many different 
approaches to coping with the disease may finally see full 
fruition in the development of a useful vaccine able to be 
utilized by the entire human population. 
Different Approaches to the Development of an HIV Vaccine 
In order to discover and promote an effective HIV 
vaccine researchers must keep certain criteria in mind. 
First the vaccine should give long-term immunity to the 
individual. In order to achieve this, accumulating 
evidence suggests that such a vaccine must efficiently 
elicit an HIV-l specific cytotoxic T lymphocyte (CTL) 
response. Although humoral or antibody responses have 
helped in the past, scientists are rapidly coming to the 
conclusion that a CTL response must occur in order for long 
term vaccination to be possible (Letvin). The ideal HIV 
vaccine would be inexpensive, easy to store and administer 
and would elicit strong, appropriate immune responses that 
confer long-lasting protection against both bloodborne and 
mucosal (sexual) exposure to many HIV sUbtypes. These 
cri teria will ensure that the entire population may take 
advantage of the new found technology, in hope that 
eventually the AIDS virus may have a similar destiny to 
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that of the small pox virus, which was eradicated from the 
face of the earth. 
Live Attenuated Virus 
Tradi tionally, the most effective viral vaccines have 
been derived from live-attenuated viruses (e.g. measles, 
mumps, rubella, oral polio, and yellow fever vaccines). A 
live attenuated vaccine based on a strain of Simian 
Immunodeficiency Virus (SIV) has long been considered the 
best hope for an AIDS vaccine. The virus would be weakened 
by the deletion of information from three genes thought to 
be necessary for causing the disease including the nef gene 
(Pantaleo et ai, 1995). Indeed, scientists have identified 
a naturally occurring attenuated HIV strains that lacks 
HIV's nef gene (Pantaleo et ai, 1995) . Among six 
Australians with this nef-deleted HIV through blood 
transfusions received between 1981 and 1984, none has 
developed HIV disease (Pantaleo et ai, 1995). These 
individuals with nature's form of the attenuated virus 
provide some information on the course of disease after 
infection, which may be helpful for the development of an 
effective attenuated vaccine. 
When used as vaccines, such attenuated viruses can 
protect monkeys against subsequent infection with the same 
and, to a lesser extent, different disease-causing strains 
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of SIV. In the SIV model, varying the number or location 
of genetically engineered deletions in the SIV genome can 
alter the level of attenuation. Preliminary results suggest 
that protective efficacy may vary inversely with the level 
of attenuation: with more deletions the vaccine becomes 
safer, but less effective (Desrosiers, 1992) . Live, 
attenuated SIV vaccines can induce a diverse and persistent 
immune response against SIV. Most likely, the protective 
efficacy seen in monkeys is immune-mediated, since levels 
of antibodies and cellular immune responses increase over 
time, and the longer one waits to challenge vaccinated 
monkeys with a pathogenic SIV, the better the protection 
(Bagarazzi et aI, 1997). Theoretically, an attenuated 
virus can elicit strong persistent antibody and cellular 
immune responses, as seen with many other vaccines that 
follow this route of action because it closely resembles 
the intact virus (British Medical Journal 317). This 
approach has been successful when tested on macaque 
monkeys, protecting them from normally lethal doses of the 
full strength virus (British Medical Journal 317). The 
trade-off to this benefit however is the potential risk 
that the modified virus will maintain some degree of 
virulence or may mutate or recombine bac~ to virulence and 
cause disease. 
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Biological companies allover the world are now in 
pursuit of developing a live attenuated virus in hopes that 
the results seen in the monkeys can be trans fer red to the 
human population. Therion Biologics of Cambridge, 
Massachusetts is one such company that is now developing a 
live attenuated vaccine, but the company shares many 
concerns about such vaccines being administered (British 
Medical Journal 317). They speculate that the weakened 
virus might cause AIDS in people with weakened immune 
systems or that the virus may revert into a more virulent 
form once it has already been administered to a patient 
(British Medical Journal 317). 
A study out of the Department of Infectious Disease 
and Microbiology at the University of Pittsburgh has 
developed a live attenuated vaccine, with a replication-
defective HIV pseudotype with vesicular stomatitis virus G 
protein (VSV-G) (Tung et aI, 1998). This pseudotyped HIV 
can infect many cell types, including human and simian 
cells, and undergoes only one round of replication (Tung et 
aI, 1998). Furthermore, antibody immune response can be 
detected in mice immunized with VSV-G-pseudotyped 
replication-defective HIV (Tung et aI, 1998). This novel 
approach to the live-attenuated version of the HIV vaccine 
may prove to be very effective at producing an immune 
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response in the body, while minimizing the potential for 
the virus to revert back into a more virulent form. 
Although there have been advances and triumphs in the 
development of a live attenuated virus, in 1995, Dr. Ruth 
Ruprecht of the Dana Farber Cancer Institute in Boston 
found that the weakened virus eventually triggered the 
simian version of AIDS when administered to baby monkeys. 
The new findings, reported at the 12th world AIDS conference 
in Geneva by Dr. Ruprecht, showed that in time the vaccine 
also cause AIDS in adult monkeys: "What we saw in infants 
is a fast forward version of what could happen in adults 
with an attenuated vaccine" (British Medical Journal 317). 
Despite these clear setbacks made obvious by the 
latest disconcerting findings, a group of about 300 doctors 
who had volunteered to be the first human to receive the 
attenuated virus plan to press ahead. "I'd take it 
tomorrow, and the others would, too," said Dr. Charles 
Farthing an AIDS specialist based in Los Angeles who is 
writing a plan for the clinical trial that will be 
submitted to the US Food and Drug Administration (FDA) 
(Bri tish Medical Journal 317). Despite the setbacks with 
the monkeys, Dr. Farthing believes that testing with an 
attenuated virus will begin within two years. 
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With the obvious discrepancies of results from various 
researchers, the encouraging finding must be balanced 
against several potentially serious risks which include 1) 
a very small fraction of individuals receiving other 
attenuated viral vaccines do develop disease, (Osborn, 
1995) 2) an attenuated AIDS vaccine may still cause disease 
in some individuals (Osborn, 1995), 3) an attenuated HIV 
might mutate, recombine, or revert to a virulent form 
(Osborn, 1995) 4 ) other viruses used to make live, 
attenuated vaccines are cleared from the body, (with the 
exception of Varicella vaccine which is apparently not 
cleared) (Behforouz, 1999) 5) HIV and possibly the 
attenuated forms insert itself into the genes of the body's 
cells and remains there for life, (Osborn, 1995) 6)other 
retroviruses which integrate into an individual's DNA and 
are known to cause cancer in animals, (al though HIV 
apparently does not lead to cancer) (Behforouz, 1999) 7) 
chronic HIV infection with an attenuated form might lead to 
the development of malignancies as well as other diseases 
apart from AIDS (Osborn, 1995). 
Gp 120 Envelope Proteins 
On the surface of the HIV virus, like many other 
viruses are envelope glycoproteins or antigens used for 
absorption to the surface of the cell. The gp 120 envelope 
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protein that is present on the HIV virion may prove to be 
an effective antigenic target for the development of a 
vaccine which could induce a humoral antibody response 
(Berman, 1998). It is the HIV-1 envelope glycoproteins that 
interact with receptors on the target cell and mediate 
virus entry by fusing the viral and cell membranes (Wyatt 
and Sodroski, 1998). It is possible to envision an antibody 
response to these glycoproteins, which could prevent 
infection particularly at mucosal surfaces by neutralizing 
the virus. The structure of the envelope glycoproteins has 
evolved to fulfill these functions while evading the 
neutralizing antibody responses of the immune system (Wyatt 
and Sodroski, 1998). A better understanding of the viral 
strategies for immune evasion should guide attempts to 
improve the immunogenicity of 
glycoproteins and, ultimately, 
development (Berman, 1998). 
the 
aid in 
HIV-1 
HIV-1 
envelope 
vaccine 
Thus far, the gp120 subunit vaccines have been given 
the most attention, with some of the vaccines now being 
cleared to enter into various clinical trials. Eighteen 
participants in a phase 1/11 clinical trial were treated 
with recombinant gp 120 subunit-vaccines. Over the course 
of the trial~ the participants became infected with HIV-l 
virus, and it was determined that only one of those who was 
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treated with the subunit-vaccines failed to develop a 
strong immunoglobin G response to the immunogen (Connor et 
aI, 1998). However, the antibody response to rpg120 was 
transient, typically having a half-life of 40 to 60 days 
(Connor et aI, 1998). The study further concluded that 
despite rigorous genetic analyses, using various breakdowns 
of data sets, no evidence that rgp120 vaccination exerted 
selective pressure on the infecting HIV-l strains could be 
found (Connor et aI, 1998). In summary, the study 
concluded that vaccination with rgp120 has had, to date no 
obvious beneficial or adverse effects on the individuals 
that that became infected during the course of the trials. 
(Connor et aI, 1998). 
Another study conducted by Lambert at the Johns 
Hopkins Uni versi ty in Baltimore researched the safety and 
immunogenicity of HIV recombinant envelope vaccines in HIV 
infected infants and children. Using Chiron rgp120 (SF-2) 
15 or 50 micrograms; MicroGeneSys rgp160 (IIIB) 40 or 320 
micrograms; Genetech rgp120 (MN) 75 or 300 micrograms; or 
adjuvant control (Alumin or MF059) , children were 
randomized to a double-blind, placebo-controlled, dose-
escalating study of vaccine administered intramuscularly at 
entry and 1,2,3,4, and 6 months later (Lambert et aI, 
1998). From the study, no adverse events were attributed 
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to the study vaccines (Lambert et al, 1998). Sixty-five 
percent of vaccinees but none of placebo recipients 
exhibited moderate or strong responses after enzyme 
immunoassay to HIV specific antigens (Lambert et al, 1998). 
The CD4 cell counts and subsequent quantitative HIV culture 
did not differ significantly among vaccine and control 
groups, nor were differences found among groups in HIV 
disease progression (Lambert et al, 1998). The study's 
final conclusion was that the rgp160 and gp120 subunit 
vaccines were safe and immunogenic in this population 
(Lambert et al, 1998). 
Wi th the progress seen in this approach to the HIV 
vaccine pursuit, the FDA has now granted permission for the 
first phase III tests of a vaccine based on this approach. 
Known as AIDSVAX, the vaccine is based on gp120 envelope 
glycoprotein. VaxGen, a subsidiary of Genentech, 
manufactures it (Josefson, 1998). The vaccine will be 
tested on 5000 US volunteers who have tested negative for 
HIV but are at high risk of contracting AIDS through sexual 
contact, and on 2500 volunteers from Thailand who are 
injecting drug users (Josefson, 1998). The phase III 
trials which are expected to last three years will compare 
vaccinated subjects with cohorts matched for age and risk 
factor, and the effect of the vaccine on AIDS prevention, 
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Al though the FDA has approved the study, many scientists 
remain skeptical. In an interview with the Wall Street 
Journal, Dr. David Baltimore, the head of the NIH sponsored 
AIDS Vaccine Research Committee, said: "I personally 
believe that people should try what they want to try, but 
it's avery, very long shot to expect anything. " Dr. 
Baltimore also raised the possibility that, when more 
effective vaccines are available, volunteers would be in 
short supply or ineligible because of participation in the 
AIDSVAX trial (Josefson, 1998). 
Al though the 
research on gp120 
federal government stopped funding 
earlier based vaccines in 1994, these 
treatments were monovalent, using envelope protein of only 
one strain of H1V (Josefson, 1998). The new vaccines that 
are now being developed utilizing the gp120 glycoprotein 
are bivalent, incorporating the two most prevalent HIV 
envelope proteins (Berman, 1998). They will also be 
tailored to reflect the most prevalent strains in the 
populations they are given to (Josefson, 1998). With 
obvious setbacks in its past, the gp120 glycoprotein 
vaccine has seen a reemergence as a possible way to curb 
the growing HIV epidemic, __ but the most promising vaccine 
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possibility lies in using HIV own genetic code encompassed 
in it's DNA as a way to lead to it's ultimate demise. 
DNA VACCINES 
AT this point in the search for a vaccine for the HIV-
1 virus type, DNA vaccine models have shown the most 
promise in being able to elicit immune reactions from both 
arms of the body's immune system, including humoral and 
cell-mediated immunity. A study by Ugen at the University 
of South Florida College of Medicine has shown that humoral 
and cellular immune responses have been produced, in mice, 
by intramuscular vaccination with DNA plasmids expressing 
HIV-l genes, suggesting possible immunotherapeutic and 
prophylactic value for these constructs. The vaccination 
wi th these constructs decreased HIV-l viral load in HIV-1 
infected chimpanzees (Ugen et aI, 1998). In addition to 
these findings, the study further showed that nal. ve (i. e. 
non HIV-1 infected) chimpanzees were protected against a 
heterologous challenge with HIV-1 (Ugen et aI, 1998). Of 
course, HIV-1 does not replicate highly in chimps and they 
do not develop disease, so one must question whether this 
is a good study model or not (Behforouz, 1999). Ongoing 
phase I clinical trials show that therapeutic vaccinations 
indeed boost anti HIV-1 immune responses in humans. More 
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importantly, these constructs showed a good safety profile 
and also immunological potential (Ugen et al, 1998). 
Other studies are now concentrating on improving the 
efficacy of the DNA vaccine, especially in regards to the 
HIV virus. A study out of the Max-von-Pettenkofer 
Institute in Munich Germany optimized codon usage of an 
injected DNA sequence to considerably increase both humoral 
and cellular immune responses. In the study, researchers 
generated a synthetic HIV-1 gp120 sequence, by replacing 
codons from the gp 120 sequence with genes expressed in 
humans (syngp12 0) . In BALB/c mice, DNA immunization with 
syngp120 resulted in significantly increased antibody 
titers and cytotoxic T-lymphocyte reactivity, suggesting a 
direct correlation between expression levels and the immune 
response (Andre et al, 1998). More importantly, however, 
is that the syngp120 is characterized by rev-independent 
expression and a low risk of recombination with viral 
sequences (Andre et al, 1998). Rev is critical for 
transport of envelope mRNA to the cytoplasm for translation 
(Behforouz, 1999) . Therefore, synthetic genes with 
optimized codon usage represent a novel strategy to 
increase the efficacy and safety of DNA vaccination against 
the HIV virus (Andre et aI, 1998). 
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Yokohama City Uni versi ty School of Medicine in Yokohama 
Japan compared the irmnune responses seen when DNA 
both vaccinations against HIV-1 were administered 
intramuscularly and intranasally in mice. Al though both 
routes of vaccination resulted in similar levels of cell-
mediated irmnuni ty, the intestinal irmnunoglobin A response 
was higher following the intranasal irmnunization (Sasaki et 
aI, 1998). This shows that the DNA vaccine has a good 
potential to be easily administered, not even making it 
necessary to inject into the muscle. 
A recent chimpanzee experiment with a DNA candidate 
vaccine demonstrated protection on challenge with HIV after 
eight irmnunizations, including two booster doses of 1&181; 
g of DNA, over a one-year period. The first phase I trial 
of an HIV envelope DNA candidate vaccine is currently 
underway. Although this approach appears promising because 
of its ease of antigen modification, some safety issues 
still remain to be addressed, such as the unlikely 
possibility of integration or recombination of DNA with 
wild virus or a possible long-term carcinogenic effect 
(Heyward et aI, 1998). 
Inactivated Viruses with Adjuvant 
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is now also a current topic of high priority in the field 
of applied immunology, especially as a means of controlling 
HIV infection (Sasaki et aI, 1998). One approach to 
optimize the response elicited by the immune system against 
the vaccine is to couple it with an adj uvant, which can 
increase the type, strength and durability of immune 
responses evoked by a vaccine (Velin et aI, 1998). Some 
vaccine antigen/adjuvant combinations can induce cell-
mediated immune responses in animals, even if the vaccine 
antigen by itself does not (Velin et aI, 1998). 
Currently, only one adjuvant-alum, first discovered in 
1926-is incorporated into vaccines licensed for human use 
by the U.S. FDA. An adjuvant may work well with one 
experimental vaccine but not another, therefore, the FDA 
licenses the vaccine formulation, or the antigen-adjuvant 
combination, rather than the adjuvant alone (Velin et aI, 
1998). Alum primarily increases the strength of antibody 
responses generated by the vaccine antigen. Because of 
alum's limited activity, other adjuvants now being 
evaluated in animal models and human studies may be better 
suited for the newer candidate HIV vaccines. 
A study by Sasaki research the effect of Ubenimex (UBX) , 
an anti-cancer immunomodulator, as an adjuvant on a DNA 
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AIDS vaccine which was developed and examined in a murine 
(mice) model. With the titers of IgG in the sera collected 
in the mice being 2-5 times higher than those inoculated 
without the use of UBX as an adjuvant, along with other 
evidence including stronger cytotoxic T lymphocyte 
acti vi ty, raised IL-2 and interferon-gamma levels, it is 
clear to see that the use of UBX as an immunologic adjuvant 
for DNA vaccination against HIV-l may be very suitable for 
clinical use because of its lack of antigenicity and low 
toxicity (Sasaki et al, 1998). 
Whole Killed or Inactivated Viral Vaccines 
Whole-killed or inactivated viral vaccines have been 
tradi tionally very effective in preventing disease (e. g. , 
inactivated polio, hepatitis A, and influenza). However, 
failed animal challenge experiments with inactivated HIV 
vaccines, as well as safety concerns over the possibility 
of incomplete inactivation or DNA integration in the host, 
have significantly impeded progress with this approach 
(Heyward et al, 1998). Overall, there was not much data 
focussing on this approach to the vaccine to be found. 
Live Vector Vaccine 
A live bacteria or virus that is harmless to humans 
and is used to transport a gene that makes HIV proteins is 
now being explored as a possible way to vaccinate against 
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HIV (Heyward et al, 1998). Current vectors that are being 
explored include vaccinia virus, canarypox, adenovirus, 
salmonella, bacille Calmette-Gueurin, and poliovirus 
(Heyward et al, 1998). The primary focus on live 
recombinant vectors concentrates on using poxvirus 
(canarypox or vaccinia). These vaccines have the ability 
to produce both neutralizing antibodies and CD8+ CTLs in 
low to moderate levels in approximately 30 to 40 percent of 
subjects (Heyward et al, 1998). 
A study out of the Division of Infectious Diseases and 
Immunology at Saint Louis University School of Medicine 
determined that the live canarypox vector was safe, 
stimulating cytotoxic T-cells and priming for a vigorous 
neutralizing antibody response upon boosting with the gp120 
subuni t vaccine (Belshe et al, 1998) . The authors 
concluded that used as a vector vaccine, the vaccine might 
have the potential for producing long term protection 
against HIV infection (Belshe et al, 1998). 
Human C1inica1 Tria1s 
Phase 1/11 Safety and Immunogenicity Trials 
Since 1987, more than 21 HIV-l preventive candidate 
vaccines have been tested in Phase I trials to assess their 
safety and immunogenicity. Although the immune correlates 
of protection against HIV infection are not known, the 
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~ first generation of candidate vaccines were aimed at 
inducing neutralizing antibodies, and most of them have 
-
been based on subunit recombinant envelope concept 
These including gp120 and gp160 envelope glycoproteins. 
first vaccines have been replaced by new candidates 
including DNA, live-attenuated virus, and live vectors, 
which are now entering Phase 1/11 clinical trials. These 
possible routes for vaccination, which were reviewed above, 
will have to move through the most important Phase III 
trials before they can be used in the human population. 
Phase III Efficacy Trials 
Although no country at this time has decided to 
proceed with a Phase III trial to determine the efficacy of 
candidate vaccines, several developed and developing 
countries are now actively preparing populations and 
research infrastructures for such trials (Esparza et aI, 
1991). These preparations include characterization of 
potential trail populations, and the establishment of 
cohorts of HIV-negative volunteers for the determination of 
HIV incidence and their willingness to participate in 
trials (Heyward, Osmanov, Saba, et at 1994);social-
behavioral studies to ensure proper educational counseling, 
and informed consent (Chesney et aI, 1995);virological 
studies to characterize incidence of HIV-l strains in trial 
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.- populations and the development of guidelines to ensure the 
highest scientific and ethical standards in the conduct of 
trials, with the appropriate participation of the 
community. 
Phase III trials will require extensive international 
collaboration and coordination, with the developing 
countries playing a major role in these trials, since some 
of the highest HIV incidence rates are found in developing 
countries, and conducting trials among these populations 
would reduce the sample size and duration of the 
trial (Cohen, 1995). More importantly, since over 90% of 
the incidence of HIV infection occurs in the third world 
countries, they would eventually benefit the most from an 
effective HIV vaccine (Cohen, 1995). Wi th the amount of 
genetic variability seen in the HIV-1 subtype, coupled with 
various co-factors and routes of transmission in different 
geographic areas, multiple efficacy trials need to be 
conducted at the same time in different parts of the world. 
In lieu of all of these hurdles necessary to move on to the 
Phase III trials, decisions to initiate the trials will be 
difficult. However, these decisions must be based not only 
on an analysis of scientific data, but also on important 
public health considerations (severity of the epidemic), as 
well the feasibility of conducting large-scale trials, 
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including: the ability to recruit and follow a large number 
of volunteers, and the political and community support to 
ensure successful implementation of the trial. 
Phase III trials will be an enormous scientific and 
social challenge, both expensive and time consuming. Some 
have raised the issue that potential vaccine efficacy trial 
'side effects' may occur, such as false expectations by the 
community that an effective vaccine will soon be available, 
with could interfere with other prevention strategies, such 
as protected sex, that are now are the only way to avoid 
the disease. Most importantly, serious rare adverse events 
such as antibody-dependent enhancement of infectivity may 
occur when large numbers of volunteers are vaccinated, and 
that a poorly designed or conducted trial, or even a trial 
with a 'no efficacy' result, may create an atmosphere of 
pessimism or rejection of further efforts to curb the HIV 
epidemic through vaccine development. 
One study conducted at the Department of Psychology, 
at Indiana University Purdue University at Indianapolis 
(IUPUI) concluded that there a number of psychosocial 
barriers to the HIV vaccine acceptance, and it cannot be 
assumed that there will be a universal acceptance for all 
people (Liau et aI, 1998)" The team of researcher:;;.~ headed 
by Liau cited the possible risk of infection as being the 
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most critical obstacle in participating in a clinical trial 
of the candidate vaccine. 
Therefore, in order to initiate a Phase III clinical 
trial, a careful risk benefit analysis must be conducted. 
Testing available candidate vaccine(s) must be weighed 
against the severity of the epidemic and the consequences 
of waiting for more data or 'better' candidate vaccines in 
the future (Mariner, 1990). 
Conc1usion 
Discussions on strategies of how to develop HIV 
vaccines are often hampered by the confrontation of two 
truisms: One states that the more information we obtain 
from basic research, the better off are we to develop more 
effecti ve HIV vaccines. The other argues that laboratory 
research alone will never be a substitute for large-scale 
clinical trials to obtain definitive information on vaccine 
efficacy (Letvin,1998). A passionate and uncompromising 
defense of either position will not help those people who 
have to take the practical decisions, nor will this 
effectively promote HIV vaccine development in general. 
Thus, a sensible strategy is to accept the uncertainties of 
proceeding with efficacy trials of available products which 
have met previously defined minimal requirements and at the 
same time continue basic research to obtain additional 
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information on the nature of protective immune responses in 
humans, some of which would likely be derived from the 
efficacy trials themselves (Haynes, 1993). 
From a practical point of view, it would be important 
to address three questions: (1) What type of additional 
information is necessary to proceed to efficacy trials with 
the greatest likelihood of success? (2) How realistic are 
the expectations that relevant information will be obtained 
from additional laboratory, animal protection or natural 
history studies in the absence of efficacy trials? (3) From 
the candidate vaccines which have entered Phase IIII 
trials, are there products that meet minimal conditions to 
proceed to Phase III trials? 
Answering the above questions is not easy. Since 
natural immune responses to HIV are complex (including both 
humoral and cellular responses) and obviously not very 
efficient, focusing laboratory research on limited aspects 
of the human immune response to HIV infection and disease 
may lead in false directions. Likewise, great uncertainties 
remain concerning the relevance of animal models as 
predictors of vaccine efficacy in humans. 
Several candidate vaccines, based on different 
concepts, are at different stages in the HIV vaccine 
development 'pipeline' (Levy, 1995). Candidate vaccines 
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based on the subunit recombinant envelope concept and 
produced in mammalian cells, have been shown to protect 
chimpanzees from HIV-l infection, 
reasonably immunogenic in humans, 
and to be safe and 
inducing neutralizing 
antibodies. A second generation of candidate vaccines, 
which are based on live vectors expressing the envelope and 
other HIV-l genes, and which are capable of inducing CTLs, 
are beginning to be evaluated in human trials. Newer 
generations of candidate vaccines now being mostly explored 
in animal experiments are using combinations of subunit 
recombinant proteins or live-vectored vaccines with other 
immunogens or are based on more novel approaches, including 
nucleic acid immunization and perhaps whole-inactivated or 
live-attenuated vaccines. 
With our present state of knowledge, it is not 
possible for laboratory assays to accurately predict which 
vaccine concept, or concepts, will induce protection 
against HIV infection in humans. Unless major advances are 
made in our understanding of the nature of protective 
immune responses to HIV-l in humans, that information will 
only be obtained through the conduct of Phase III field 
efficacy trials. However, in view of the rate of 
progression of the HIV pandemic, especially in developing 
countries, it would not be ethical to wait in the hope that 
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such advances will occur soon, thus postponing trials with 
candidate vaccines (Heyward, Osmanov, Saba, et aI, 1994). 
In fact these trials, conducted in parallel or 
sequentially, may represent our best chance to enhance our 
basic knowledge of the nature of protecti ve immune 
responses to HIV infection. 
Thus, in order to avoid the unacceptable al ternati ve 
of perpetual uncertainty, or to delay the development of a 
much-needed vaccine, there is no other choice but to 
effectively integrate further basic research with the 
initiation of large-scale field efficacy trials in the 
process of HIV vaccine development. These Phase III trials 
will present unique opportunities to: (1) establish if 
different vaccine concepts can induce protection in humans; 
(2) validate the primate models presently being used in HIV 
vaccine research; (3 ) obtain information on immune 
correlates of vaccine-induced protection; (4) explore the 
significance of viral genetic variability in relation to 
vaccine-induced protection; (5) evaluate different end-
points for vaccine efficacy (prevention of infection, 
establishment of chronic infection, or disease); and (6) 
generate additional data on vaccine safety (Heyward et aI, 
1997) . 
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The development of an HIV vaccine will be a long and 
difficult process. Multiple efficacy trials and case-
control studies will ultimately be required before a safe, 
effective and affordable vaccine is available for 
widespread public health use. With more than 6000 new 
infections occurring every day worldwide, there is urgency 
to proceed. 
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